Skip to main content

Vyvgart News

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefilled Syringe for Self-Injection

April 10, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S....

FDA Approves Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

Breda, the Netherlands—Dec. 17, 2021 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and c...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Myasthenia Gravis

Vyvgart patient information at Drugs.com